Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome.
Seven children with Guillain-Barré syndrome were treated with intravenous immunoglobulin. Median patient age was 5.8 years. A standard dosage of 0.4 g/kg/day for 5 days was administered. Clinical improvement occurred on average within 2.4 +/- 1.3 days of beginning intravenous immunoglobulin. One child required mechanical ventilation for 7 days. Eight comparable children with Guillain-Barré syndrome at our institution in a prior study treated with plasmapheresis alone had similar clinical results. However, the need for admission to the pediatric intensive care unit and duration of pediatric intensive care unit stay were lower in the intravenous immunoglobulin treated group (P < .05). There were no complications with intravenous immunoglobulin therapy except for a brief episode of hypotension in one patient. Review of the literature identified 74 additional children with Guillain-Barré syndrome successfully receiving intravenous immunoglobulin therapy. We suggest intravenous immunoglobulin as initial therapy for pediatric Guillain-Barré syndrome, because it appears equally as effective as plasmapheresis and is associated with fewer complications.
Abd-Allah
S A
SA
Department of Pediatrics, Loma Linda University Children's Hospital, CA 92350, USA.
Jansen
P W
PW
Ashwal
S
S
Perkin
R M
RM
D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003422:Critical Care / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000592:standards*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D010956:Plasmapheresis / Q000009:adverse effects / Q000592:standards; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology; D012121:Respiration, Artificial / Q000706:statistics & numerical data; D012189:Retrospective Studies; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous